{"id":"W2594219762","doi":"10.1182/blood.v112.11.3232.3232","title":"Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dasatinib; Medicine; Nilotinib; Dosing; Adverse effect; Internal medicine; Pharmacology; Imatinib mesylate; Imatinib; Gastroenterology; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009906471,0.001384843,0.0009778603,0.0001944381,0.0003203147,0.000752816,0.0004625343,0.0007825102,0.003589954],"category_scores_gemma":[0.0005598505,0.0003150964,0.0008835958,0.0001887908,0.000581763,0.0005410534,0.0002541666,0.002167894,0.0008864094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005391653,"about_ca_system_score_gemma":0.0007569841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009802338,"about_ca_topic_score_gemma":0.002728276,"domain_scores_codex":[0.9997601,0.0001063697,0.00001261067,0.00003231667,0.0000198553,0.00006873431],"domain_scores_gemma":[0.9994863,0.0001024559,0.00006221369,0.0000262323,0.00002431458,0.0002984082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.486738,0.06414014,0.01837462,0.001330499,0.001371501,0.001726305,0.000820812,0.007300345,0.1695993,0.0007094531,0.02002957,0.2278595],"study_design_scores_gemma":[0.3125385,0.6407531,0.02368446,0.00005503618,0.0004222277,0.001071984,0.00009630243,0.002412697,0.01198325,0.0003540213,0.006585239,0.00004312467],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890805,0.001722988,0.0009044665,0.0007844734,0.0001054832,0.001711899,0.001713001,0.0001704666,0.003806693],"genre_scores_gemma":[0.9907216,0.001228252,0.001008422,0.0006562626,0.00009974581,0.001044593,0.002673061,0.00003102835,0.002536995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003589954,"threshold_uncertainty_score":0.01200962,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02453603128584829,"score_gpt":0.2890415884862166,"score_spread":0.2645055572003683,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}